The effects of atropine and glycopyrrolate on anatomical dead space, one and three second forced expiratory volume, maximal expiratory flow rate, and total forced expiratory volume were determined in ten healthy volunteers. Using Fowler's single breath nitrogen analyzing technique, atropine was found to increase dead space by 19.2 per cent at one hour, declining to 11.02 per cent at four hours. Glycopyrrolate increased dead space by 21.57 per cent at one hour, 29.28 per cent at two hours, and 26.65 per cent at four hours. When compared to the effects of saline control injection, the dead space increases are significant. The difference between glycopyrrolate and atropine is significant only at four hours. Increases in maximal expiratory flow rate induced by atropine and glycopyrrolate were significant at one-half hour, while atropine alone induced a significant increase in one second forced expiratory volume. Three second forced expiratory volume and total forced expiratory volume were not significantly altered.
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METHOD
The protocol for this study was approved by the Clinical Investigations Committee of the Memorial Sloan-Kettering Cancer Center.
Ten non-smoking, healthy volunteers (seven males, three females, aged 23-32 years), reported to the laboratory early in the morning, after an overnight fast. The nature of the experiment, side effects and hazards of the drugs involved were explained in detail, and informed consent was obtained. After familiarization with the Hewlett Packard 47402A Pulmonary Function Analyzer, base line determinations were made of anatomical dead space (VD anat), using Fowler's single breath nitrogen analyzing technique, s One and three second forced expiratory volume (FEV~, FEV~), total forced expiratory volume (FEV) and maximal expiratory flow rate (MEFR) were also measured. The maximal expiratory flow rate is the forced expiratory flow rate between 200 and 1200 ml expired gas. All tests were done with the subjects seated comfortably and they were allowed to rest or walk at will between studies, but were not to exert themselves. In a randomized double-blind manner each subject then received atropine sulphate 0.0085 rag-kg -~ body weight, glycopyrrolate 0.005 rag. kg -1 body weight, and sterile saline solution one ml intramuscularly, one drug on each of three consecutive days. The injections were made into the deltoid muscle of alternate arms. Repeat determinations of all studies were done for the next four hours, with the timed forced expiratory volume and MEFR beginning at one-half hour and repeated at hourly intervals. The first repeat dead space determination was made at one hour, and repeated at hourly intervals. Dead space and forced expiratory curves were recorded graphically, and volumes measured at BTPS. Dead space determinations were measured by Fowler's "estimation" technique of equal areas. S Alterations in the determined parameters were expressed as percentage increase or decrease from pre-drug measurements, and the mean changes tested for significance against values for the saline controls, using Student's t test. Findings were considered significant at a P< 0.05 level.
RESULTS
The pre-drug anatomical dead space averaged 155ml in the seven males (l.98ml/kg body weight), and 132ml in the three females (2.42 ml/kg body weight). Both atropine and glycopyrrolate increased dead space in all subjects, the mean increase for atropine being 19.2 per cent at one hour and declining to ! 1.02 per cent at 4 hours. The dead space increases were at all times significant (P < 0.01, with atropine significant at two hours, P< 0.05). The mean increase in dead space caused by glycopyrrolate was 21.57 per cent at one hour and increasing further to 26.65 per cent at four hours (Table I) . These increases are significant at all times (P< 0.01). Although all subjects had an increase of dead space in response to atropine and glycopyrrolate, there was great individual variation, maximal increases ranging from 10.3 per cent to 50 per cent for atropine, and 6.7 to 60.7 per cent for glycopyrrolate. The difference between atropine and glycopyrrolate is not significant except at four hours, when the glycopyrrolate-induced increase in dead space is significantly greater than that for atropine (P < 0.05). The increase in dead space caused by glycopyrrolate at one hour did not vary significantly from the glycopyrrolate increases at either two, three, or four hours. Thus, the increase of dead space caused by glycopyrrolate was maximal within two hours, and lasted at least four hours without declining, while the increase produced by atropine was maximal within one hour, but was definitely declining by four hours.
Both atropine and glycopyrrolate increased the one second forced expiratory volume (Table I1 ). The atroplne-induced increases are significant (P < 0.05) except at 3 89 hours. The glycopyrrolate changes are not significant.
Although the maximal expiratory flow rate was Alterations in anatomical dead space after atropine sulphate 0.008.$ mg.kg -x body weight, glycopyrrolate 0.005 mg-kg -1, or normal saline 1 ml intramuscularly. Dead space was increased significantly by both atropine and glycopyrrolate at all times, when compared to saline control. The glycopyrrolate-induced increase is significantly greater than that of atropine only at four hours. Alterations in one second forced expiratory volume after atropine, glycopyrrolate or saline intramuscularly. The atropine changes are significant, except at 3~-hours. The glycopyrrolate changes are not significant. Alteration in maximal expiratory flow rate after atropine, glycopyrrolate and saline intramuscularly. The changes for both atropine and glycopyrrolate are significant only at { hour.
increased by both atropine and glycopyrrolate (see Table III ), the changes were significant only at one-half hour (P < 0.05). Total forced expiratory volume and three second forced expiratory volume were not changed.
DISCUSSION
In 1915 Higgins and Means demonstrated the ability of atropine to increase anatomical dead space by 6.73 per cent in one subject, and by 15.48 per cent in another, determinations being made two hours after the subcutaneous administration of atropine 1 mg.1 Fowler's development of the single breath nitrogen analyzing technique gave a reliable method of determining anatomical dead space, s His base line dead space averaged 156 ml in males (2.13 ml/kg) and 120 ml in females (l.91 ml/kg). Using Fowler's technique, Severinghaus demonstrated an increase of 29 per cent in anatomical dead space 40 minutes after atropine 0.5 mg subcutaneously, and 47 per cent when the drug was administered intravenously. 2 He also showed that any atropine-induced increase in dead space was maximal, in that it was not increased by epinephrine after atropine. 9 Nunn found an increase of 12.7 per cent in dead space 15 minutes after atropine sulphate 0.6mg intravenously. 3 Both Higgins and Nunn attributed increases in respiratory minute volume after atropine to attempts to maintain normocapnia by hyperventilation. The broncho-dilating ability of atropine has also been demonstrated radiographically in dogs, increasing the diameter of trachea and primary bronchi by 20 per cent and lobar bronchi by 9.7 per cent.'~ The marked increase in anatomical dead space, with smaller decreases in resistance to air flow is probably attributable to the ability of atropine to dilate smaller conducting airways more than larger airways. TM Glycopyrrolate emulates the ability of atropine to increase dead space significantly with only minor alterations in airway resistance. Since 80 per cent of tracheobronchial resistance resides in the larger conducting bronchi, an increase in diameter predominantly in the smaller tubules would produce a marked increase in dead space, while at the same time having a significantly lesser effect on airway resistance. Smaller tubules may be considered as those two mm or less in diameter and are the fifth to eighteenth generation of air tubule.' t
The bronchodilating effect of atropine is evident within 15 minutes of injection. Earlier studies have been single tests at one time period, and have not demonstrated the duration of the bronchodilating effect. The effect of atropine on heart rate is maximal at 30 minutes after intramuscular injection, with a return to near predrug levels at 3 hours, and exact pre-drug levels at 5 hours.': The duration of the bronchodilating effect of atropine is thus similar to its effect on heart rate. Blood levels of atropine are maximal 15-50 minutes after intramuscular injection. '2 Earlier studies of glycopyrrolate indicate that its course of action is longer than that of atropine while its anticholinergic intensity is similar. Our study indicates that the bronchodilating effect of glycopyrrolate is similar in magnitude to that of atropine, but longer in duration. Although both drugs produced a significant drying effect, there was no difference between the subjective feelings of discomfort produced by either drug. Nausea and vomiting did not occur. ,3 SUMMARY Both atropine and glycopyrrolate in usual pre-medicant doses increase anatomic dead space while, at the same time, they cause minor alterations in pulmonary air flow. These changes are attributable to dilation of smaller bronchioles.
